Hubbry Logo
Contact dermatitisContact dermatitisMain
Open search
Contact dermatitis
Community hub
Contact dermatitis
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Contact dermatitis
Contact dermatitis
Contact dermatitis
View on Wikipedia
from Wikipedia
Contact dermatitis
Contact dermatitis rash.
SpecialtyDermatology

Contact dermatitis is a type of acute or chronic inflammation of the skin caused by exposure to chemical or physical agents.[1] Symptoms of contact dermatitis can include itchy or dry skin, a red rash, bumps, blisters, or swelling. These rashes are not contagious or life-threatening, but can be very uncomfortable.

Contact dermatitis results from either exposure to allergens (allergic contact dermatitis), or irritants (irritant contact dermatitis). Allergic contact dermatitis involves a delayed type of hypersensitivity and previous exposure to an allergen to produce a reaction.[2] Irritant contact dermatitis is the most common type and represents 80% of all cases.[1] It is caused by prolonged exposure to irritants, leading to direct injury of the epidermal cells of the skin, which activates an immune response, resulting in an inflammatory cutaneous reaction.[1] Phototoxic dermatitis occurs when the allergen or irritant is activated by sunlight. Diagnosis of allergic contact dermatitis can often be supported by patch testing.[3]

Epidemiology

[edit]

Contact dermatitis constitutes 95% of all occupational skin disorders.[4] There are few accurate statistics on the incidence and prevalence of contact dermatitis.[5] The results of the few studies that have been undertaken cannot be compared because of methodological differences.[5]

Signs and symptoms

[edit]

Contact dermatitis is a localized rash or irritation of the skin caused by contact with a foreign substance. Only the superficial regions of the skin are affected in contact dermatitis. Inflammation of the affected tissue is present in the epidermis (the outermost layer of skin) and the outer dermis (the layer beneath the epidermis).[6]

Contact dermatitis results in large, burning, and itchy rashes. These can take anywhere from several days to weeks to heal. This differentiates it from contact urticaria (hives), in which a rash appears within minutes of exposure and then fades away within minutes to hours. Even after days, contact dermatitis fades only if the skin no longer comes in contact with the allergen or irritant.[7] Chronic contact dermatitis can develop when the removal of the offending agent no longer provides expected relief.[citation needed]

Irritant dermatitis is usually confined to the area where the irritating substance actually touched the skin, whereas allergic dermatitis may be more widespread on the skin. Irritant dermatitis is usually found on hands whereas exposed areas of skin. Symptoms of both forms include the following:

  • Red rash: This is the usual reaction. The rash appears immediately in irritant contact dermatitis; in allergic contact dermatitis, the rash sometimes does not appear until 24–72 hours after exposure to the allergen.
  • Blisters or wheals: Blisters, wheals (welts), and urticaria (hives) often form in a pattern where skin was directly exposed to the allergen or irritant.
  • Itchy, burning skin: Irritant contact dermatitis tends to be more painful than itchy, while allergic contact dermatitis often itches.
  • The surface appearance of skin: Skin is dry and fissured in the irritant contact dermatitis whereas vesicles and bullae are seen in allergic contact dermatitis.[8]
  • Lichenified lesions:[1]

While either form of contact dermatitis can affect any part of the body, irritant contact dermatitis often affects the hands, which have been exposed by resting in or dipping into a container (sink, pail, tub, swimming pools with high chlorine) containing the irritant.[citation needed]

Causes

[edit]

The percentage of cases attributable to occupational contact dermatitis varies substantially depending on the industries that predominate, the employment that people have, the risks to which they are exposed, the centers that record cases, and variances in defining and confirming diagnoses.[9]

Common causes of allergic contact dermatitis include: nickel allergy, 14K or 18K gold, Balsam of Peru (Myroxylon pereirae), and chromium. In the Americas they include the oily, urushiol-containing coating from plants of the genus Toxicodendron: poison ivy, poison oak, and poison sumac. Millions of cases occur each year in North America alone.[10] The alkyl resorcinols in Grevillea banksii and Grevillea 'Robyn Gordon' are responsible for contact dermatitis.[11] Bilobol, another alkyl resorcinol found in Ginkgo biloba fruits, is also a strong skin irritant.[12]

Common causes of irritant contact dermatitis include solvents, metalworking fluids, latex, kerosene, ethylene oxide, paper, especially papers coated with chemicals and printing inks, certain foods and drink,[13] food flavorings and spices,[14] perfume,[13] surfactants in topical medications and cosmetics, alkalis, low humidity from air conditioning, and many plants. Other common causes of irritant contact dermatitis are harsh alkaline soaps, detergents, and cleaning products.[15]

There are three types of contact dermatitis: irritant contact dermatitis; allergic contact dermatitis; and photocontact dermatitis. Photocontact dermatitis is divided into two categories: phototoxic and photoallergic.

Irritant contact dermatitis

[edit]
Main article: Irritant contact dermatitis

The irritant's direct cytotoxic impact on epidermal keratinocytes causes Irritant contact dermatitis.[1] This disrupts the skin barrier and activates the innate immune system. Keratinocytes in the epidermis can be actually affected by irritants.[1] It is a complicated reaction that is influenced by genetic and environmental elements, both of which have a role in the pathogenesis of the disease.[1] It can be seen in both occupational and non-occupational environments but it's more common in the occupations dealing in low humidity conditions.[1]

Contact dermatitis caused by unprotected handling of damp, impregnated wooden construction debris.

Irritant contact dermatitis (ICD) can be divided into forms caused by chemical irritants, and those caused by physical irritants. Common chemical irritants implicated include: solvents (alcohol, xylene, turpentine, esters, acetone, ketones, and others); metalworking fluids (neat oils, water-based metalworking fluids with surfactants); latex; kerosene; ethylene oxide; surfactants in topical medications and cosmetics (sodium lauryl sulfate); and alkalis (drain cleaners, strong soap with lye residues).[citation needed]

Physical irritant contact dermatitis may most commonly be caused by low humidity from air conditioning.[16] Also, many plants directly irritate the skin.

Allergic contact dermatitis

[edit]
Main article: Allergic contact dermatitis
Three-year-old girl with contact dermatitis, one day after contact with poison ivy

Allergic contact dermatitis (ACD) is accepted to be the most prevalent form of immunotoxicity found in humans, and is a common occupational and environmental health problem.[17] By its allergic nature, this form of contact dermatitis is a hypersensitive reaction that is atypical within the population. The development of the disease occurs in two phases, which are induction and elicitation.[17] The process of skin sensitization begins when a susceptible subject is exposed to the allergen in sufficient concentration to elicit the required cutaneous immune response. This causes sensitization and when exposure to the same allergen at a later time at the same or different skin site leads to a secondary immune response at the point of contact.[17] The mechanisms by which this reaction occurs are complex, with many levels of fine control. Their immunology centres on the interaction of immunoregulatory cytokines and discrete subpopulations of T lymphocytes.[citation needed]

Allergens include nickel, gold, Balsam of Peru (Myroxylon pereirae), chromium, and the oily coating from plants of the genus Toxicodendron, such as poison ivy, poison oak, and poison sumac. Acrylates, rubber chemicals, emulsifiers and dyes, epoxy resin chemicals are just several of the substances that might induce Allergic Contact Dermatitis.[17] Much of the allergic contact dermatitis that arises is caused by occupational exposure. Non-occupational exposure to allergens in medicaments, clothing, cosmetics, and plants are also a significant cause of allergic contact dermatitis.[17]

Photocontact dermatitis

[edit]
Main article: Phytophotodermatitis

Sometimes termed "photoaggravated",[18] and divided into two categories, phototoxic and photoallergic, PCD is the eczematous condition which is triggered by an interaction between an otherwise unharmful or less harmful substance on the skin and ultraviolet light (320–400 nm UVA) (ESCD 2006), therefore manifesting itself only in regions where the affected person has been exposed to such rays.[citation needed]

Without the presence of these rays, the photosensitiser is not harmful. For this reason, this form of contact dermatitis is usually associated only with areas of skin that are left uncovered by clothing, and it can be soundly defeated by avoiding exposure to sunlight.[19] The mechanism of action varies from toxin to toxin, but is usually due to the production of a photoproduct. Toxins which are associated with PCD include the psoralens. Psoralens are in fact used therapeutically for the treatment of psoriasis, eczema, and vitiligo.[citation needed]

Photocontact dermatitis is another condition in which the distinction between forms of contact dermatitis is not clear-cut. Immunological mechanisms can also play a part, causing a response similar to ACD.

Diagnosis

[edit]
Patch test

Since contact dermatitis relies on an irritant or an allergen to initiate the reaction, it is important for the patient to identify the responsible agent and avoid it. This can be accomplished by having patch tests, one of various methods commonly known as allergy testing.[20] The patch tests were based on the concept of a type IV hypersensitivity reaction where there is exposure of allergens to skin and checking for the development of contact dermatitis in that area. This test involves the application of suspected irritant to a part of the skin and cover it with impermeable material and attached to the skin with the help of adhesive plaster.[21] The top three allergens found in patch tests from 2005 to 2006 were: nickel sulfate (19.0%), Myroxylon pereirae (Balsam of Peru, 11.9%), and fragrance mix I (11.5%).[22] The patient must know where the irritant or allergen is found to be able to avoid it. It is important to also note that chemicals sometimes have several different names, and do not always appear on labels.[23]

The distinction between the various types of contact dermatitis is based on a number of factors. The morphology of the tissues, the histology, and immunologic findings are all used in diagnosis of the form of the condition. However, as suggested previously, there is some confusion in the distinction of the different forms of contact dermatitis.[24] Using histology on its own is insufficient, as these findings have been acknowledged not to distinguish,[24] and even positive patch testing does not rule out the existence of an irritant form of dermatitis as well as an immunological one.

Prevention

[edit]

In an industrial setting the employer has a duty of care to its worker to provide the correct level of safety equipment to mitigate exposure to harmful irritants. This can take the form of protective clothing, gloves, or barrier cream, depending on the working environment. It is impossible to eliminate the complete exposure to harmful irritants but can be avoided using the multidimensional approach. The multidimensional approach includes eight basic elements to follow. They are:

  • Identification of possible cutaneous irritants and allergens
  • To avoid skin exposure, use appropriate control measures or chemical substitutes.
  • Personal protection can be achieved by the use of protective clothes or barrier creams.
  • Maintenance of personal and environmental hygiene
  • Use of harmful irritants in the workplace should be regulated
  • Efforts to raise knowledge of potential allergies and irritants through education
  • promoting safe working conditions and practices
  • health screenings before and after employment and on a regular basis[25]

Topical antibiotics should not be used to prevent infection in wounds after surgery.[26][27] When they are used, it is inappropriate, and the person recovering from surgery is at significantly increased risk of developing contact dermatitis.[26]

Treatment

[edit]

Self-care

[edit]
  • If blistering develops, cold moist compresses[28] applied for 30 minutes, three times a day can offer relief.
  • Calamine lotion may relieve itching.[28]
  • Oral antihistamines such as diphenhydramine (Benadryl, Ben-Allergin) can relieve itching.[28]
  • Avoid scratching.[28]
  • Immediately after exposure to a known allergen or irritant, wash with soap and cool water to remove or inactivate most of the offending substance.
  • For mild cases that cover a relatively small area, hydrocortisone cream in nonprescription strength may be sufficient.
  • Weak acid solutions (lemon juice, vinegar) can be used to counteract the effects of dermatitis contracted by exposure to basic irritants.
  • A barrier cream, such as those containing zinc oxide (e.g., Desitin, etc.), may help protect the skin and retain moisture.

Medical care

[edit]

If the rash does not improve or continues to spread after two to three of days of self-care, or if the itching and/or pain is severe, the patient should contact a dermatologist or other physician. Medical treatment usually consists of lotions, creams, or oral medications.

  • Corticosteroids. A corticosteroid medication like hydrocortisone may be prescribed to combat inflammation in a localized area. It may be applied to the skin as a cream or ointment. If the reaction covers a relatively large portion of the skin or is severe, a corticosteroid in pill or injection form may be prescribed.

In severe cases, a stronger medicine like halobetasol may be prescribed by a dermatologist.

  • Antihistamines. Prescription antihistamines may be given if non-prescription strengths are inadequate.

See also

[edit]

References

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Contact dermatitis

View on Grokipedia
from Grokipedia
Contact dermatitis is a prevalent inflammatory characterized by an itchy, red rash that develops upon direct exposure to an environmental irritant or , affecting the skin at the site of contact without being contagious. It encompasses two primary types: , the more common form resulting from non-immune-mediated damage to the skin barrier by substances like soaps, detergents, or solvents, and , a type IV delayed reaction triggered by immune sensitization to allergens such as , fragrances, or plants like . The condition impacts an estimated 15-20% of the general population, with higher rates among women and those in occupations involving frequent chemical exposure, such as healthcare or . Symptoms typically appear within hours to days after exposure and include , , pruritus, and in severe cases, vesicles, bullae, or crusting, often localized to areas like the hands, face, or legs depending on the contact source. Common irritants encompass everyday items such as gloves, products, and industrial chemicals, as well as chemical residues in unwashed clothing (particularly second-hand or new garments), including detergents, fabric softeners, and moth repellents. Allergens frequently involve metals, rubber additives, preservatives in , and topical medications like neomycin, as well as textile dyes and chemical finishes such as formaldehyde resins. Risk factors include a history of , fair skin, and prolonged or repeated exposure, with occupational contact dermatitis accounting for a significant portion of cases, estimated at 0.5-1.9 per 1,000 workers annually. Diagnosis primarily relies on clinical history and examination, supplemented by patch testing to identify specific in suspected allergic cases, while treatment focuses on or irritant avoidance as the cornerstone, alongside topical corticosteroids for , moisturizers to restore the skin barrier, and oral antihistamines or systemic steroids for severe reactions. Most cases resolve within weeks with proper management, though chronic exposure can lead to persistent or recurring , emphasizing the importance of preventive measures like protective and hypoallergenic products.

Definition and Classification

Definition

Contact dermatitis is an inflammatory eczematous skin disease resulting from direct contact with external substances that exert toxic effects or trigger immunologic responses, such as irritants or allergens. It is characterized by a localized confined to the site of exposure, which may appear acutely with sudden onset or chronically with persistent symptoms, and is distinctly non-contagious. This condition differs from other dermatitides, such as , which is endogenous and driven by internal factors like genetic and immune dysregulation, or infectious causes like fungal or bacterial involvement that spread via pathogens. In contrast, contact dermatitis arises solely from exogenous environmental triggers without systemic spread or contagion. Descriptions of skin reactions resembling contact dermatitis to external agents, such as plants, appear in ancient dating back over 3,500 years. The modern classification of its allergic subtype was established through Josef Jadassohn's development of patch testing in 1895, enabling the diagnosis of reactions to specific contactants. There are two primary types—irritant and allergic—though further details on their distinctions are covered elsewhere.

Types

Contact dermatitis is broadly classified into irritant and allergic forms based on the underlying immunologic mechanisms, with additional subtypes distinguished by specific triggering factors such as light exposure or of allergens. Contact dermatitis can also present in acute or chronic forms, depending on the duration and intensity of exposure. This classification emphasizes whether the reaction involves immune-mediated or direct non-immunologic tissue damage, guiding diagnosis and . (ICD) represents the most prevalent type, accounting for approximately 80% of all cases, and arises from a non-immunologic, dose-dependent inflammatory response to external substances that disrupt the skin barrier without prior . In contrast, (ACD) is an immunologic reaction characterized by delayed , requiring initial cutaneous followed by re-exposure to the eliciting agent. Photocontact dermatitis constitutes a specialized subtype where ultraviolet light interacts with contactants on the skin, leading to either phototoxic or photoallergic reactions; phototoxic variants mimic irritant responses through direct cellular upon photoactivation, while photoallergic forms involve an immune-mediated process akin to ACD but triggered by light-modified haptens. Occupational contact dermatitis is not a distinct immunologic category but rather a context-specific manifestation, encompassing both ICD and ACD patterns that predominate in work-related exposures, often affecting the hands due to repetitive contact with workplace materials. Similarly, systemic contact dermatitis occurs in previously sensitized individuals upon internal exposure (e.g., via ingestion or injection) to allergens, resulting in widespread eczematous eruptions that extend beyond sites of prior contact. These rarer variants highlight how extends beyond simple irritant-allergic dichotomies to incorporate environmental and exposure-route modifiers.

Epidemiology

Prevalence and Incidence

Contact dermatitis is a common , affecting an estimated 15-20% of the general over their lifetime. This encompasses both (ICD) and (ACD), with ICD comprising approximately 80% of cases due to its association with direct chemical or physical irritants, while ACD accounts for the remaining 20% and involves immune-mediated . These figures highlight the condition's widespread impact, though exact rates vary by diagnostic criteria and studied. The annual incidence of contact dermatitis in the general population is estimated at 7.9 new cases per 1,000 persons per year based on a large cohort study. For allergic contact dermatitis, approximately 5-10% of the population may experience clinical symptoms at least once per year, particularly in settings with frequent exposure to potential triggers. Occupational environments show markedly higher rates; for instance, prevalence among healthcare workers ranges from 20% to 30%, driven by repeated handwashing, glove use, and disinfectant exposure. Cohort studies report incidence rates in this group from 15.9 to 78 per 10,000 person-years, underscoring the burden in high-risk professions. Geographic variations reflect socioeconomic and environmental factors, with higher prevalence observed in industrialized countries due to increased chemical exposures from manufacturing, consumer products, and urban lifestyles. For example, occupational contact dermatitis is the leading work-related skin disease in such regions, contrasting with lower rates in less developed areas with reduced industrial activity. Overall prevalence has remained relatively stable over recent decades, but specific trends indicate a rise in ACD cases linked to fragrances and preservatives, as evidenced by data from 2014 to 2023 showing increased sensitization rates to these common cosmetic ingredients. This uptick, noted in reports, aligns with growing use of and highlights the need for ongoing surveillance.

Risk Factors

Contact dermatitis affects individuals across all ages, though it peaks in among working adults, particularly those aged 25 to 44 years, due to occupational exposures. Prevalence is lower in children and adolescents (around 14.5%) compared to adults (21%). Women experience the condition at a higher rate than men, with a female-to-male ratio of approximately 2:1, primarily owing to increased use of and household cleaning products. Certain occupations heighten the risk through repeated contact with irritants and allergens. Healthcare workers face elevated exposure to gloves and disinfectants, while hairdressers encounter hair dyes, shampoos, and bleaches; manufacturing roles often involve metals like and , as well as solvents and oils. These professions account for a significant portion of occupational contact dermatitis cases, with rates up to 20-30% in some high-risk groups. Environmental exposures further amplify susceptibility, including frequent hand wetting from water or soaps, which can disrupt the skin barrier, and direct contact with plants containing or other sensitizers. An atopic background, such as a history of eczema or , substantially increases the risk for by promoting skin permeability and immune dysregulation. Genetic factors play a role in vulnerability, notably loss-of-function mutations in the gene (FLG), which impair the skin's natural moisturizing factor and barrier integrity, leading to drier skin and greater allergen penetration. Recent data highlight a surge in cases linked to since 2020, driven by heightened use of hand sanitizers and hygiene items during the .

Pathophysiology

Irritant Mechanisms

Irritant contact dermatitis arises from non-immunologic mechanisms involving direct damage to the by external chemical or physical agents, without the involvement of adaptive immunity. These irritants exert toxic effects on skin cells, primarily in the , leading to cellular injury and subsequent inflammatory responses driven by innate immunity. Unlike allergic reactions, irritant mechanisms do not require prior and are characterized by a dose-dependent threshold below which no reaction occurs. A primary mechanism is direct , where irritants such as solvents and detergents disrupt the , the outermost layer of the skin barrier. This disruption compromises the lipid matrix and corneocyte structure, increasing and allowing penetration of further irritants or microbes. For instance, in detergents solubilize , leading to rapid barrier breakdown and epidermal cell death through membrane damage and protein denaturation. Following barrier impairment, an inflammatory cascade is initiated without T-cell involvement, relying instead on the rapid release of proinflammatory from damaged and resident immune cells. Key mediators include interleukin-1 (IL-1) and tumor necrosis factor-alpha (TNF-α), which amplify by recruiting neutrophils and monocytes, promoting , and stimulating further cytokine production such as IL-6 and IL-8. This innate response results in localized and , perpetuating the irritant effect through a feedback loop of cellular activation. The severity and progression of irritant contact dermatitis follow a dose-response relationship, where the intensity of exposure determines the clinical outcome. Acute occurs with high-dose, single exposures to strong irritants, such as acids or alkalis, causing immediate akin to chemical burns with rapid onset of and . In contrast, cumulative develops from repeated low-dose exposures to milder irritants, like or soaps in occupational wet work, leading to chronic barrier dysfunction and adaptive skin changes including and acanthosis as the thickens in response to ongoing insult.

Allergic Mechanisms

Allergic contact dermatitis represents a type IV delayed-type reaction mediated by T cells, triggered by exposure to environmental haptens in previously individuals. This immunologic process involves two distinct phases: and elicitation, both centered on the of adaptive immune responses in the skin. Unlike immediate reactions, the response develops over 24 to 72 hours due to the involvement of antigen-specific memory T cells. In the sensitization phase, low-molecular-weight haptens penetrate the and covalently bind to endogenous skin proteins, forming complete immunogenic complexes. These -protein conjugates are captured and processed by epidermal Langerhans cells, which are dendritic cells that migrate to draining lymph nodes. There, they present the antigens via ( and II molecules to naïve CD8+ cytotoxic T cells and CD4+ helper T cells, respectively, leading to their priming, proliferation, and differentiation into effector and memory T cells. Cytokines such as interleukin-1 (IL-1) from and Langerhans cells further support this T-cell activation. A classic example is , a common that binds to residues in proteins, rendering them allergenic and initiating this cascade. The elicitation phase occurs upon re-exposure to the same , where resident memory T cells in the are rapidly reactivated. Hapten-specific CD8+ T cells predominate, releasing interferon-gamma (IFN-γ) and tumor necrosis factor-alpha (TNF-α), which recruit additional inflammatory cells and induce keratinocyte , resulting in the characteristic eczematous reaction. CD4+ T cells contribute by amplifying the response through production, including IL-17 in some cases. This phase highlights the role of tissue-resident memory T cells (T_RM), which provide long-term skin immunity without systemic recirculation. In chronic allergic contact dermatitis, persistent hapten exposure sustains T-cell mediated inflammation, leading to epidermal , , and eventual dermal due to prolonged signaling. influences susceptibility, with variants in the IL-16 promoter (e.g., -295 T to C transition) associated with increased risk of sensitization and chronic inflammation by enhancing chemoattraction of CD4+ T cells. This homozygous CC correlates with higher IL-16 expression, exacerbating Th1-driven responses in affected individuals.

Photocontact Mechanisms

Photocontact dermatitis results from the interaction between (UV) radiation and photoactive chemicals applied topically or absorbed systemically, leading to distinct phototoxic or photoallergic reactions confined primarily to sun-exposed areas. These mechanisms differ from standard by requiring simultaneous exposure to activate the chemical, which otherwise remains inert. Phototoxic reactions are non-immunologic and dose-dependent, occurring when a photoactive substance absorbs UV light and undergoes photochemical reactions that directly damage keratinocytes and other skin cells. Upon light absorption, the chemical enters an excited state, often generating reactive oxygen species (ROS) such as singlet oxygen or superoxide radicals, which induce lipid peroxidation, DNA damage, and membrane disruption in epidermal cells. A classic example is psoralens found in plants like celery or figs; these furocoumarins intercalate into DNA and, under UVA irradiation (320–400 nm), form cyclobutane pyrimidine adducts, exacerbating cytotoxicity and leading to rapid onset of inflammation resembling exaggerated sunburn. UVB (290–320 nm) can also trigger phototoxicity in certain compounds, though UVA is more commonly implicated due to its deeper skin penetration. In contrast, photoallergic reactions are immunologic and immunogenic, resembling delayed-type (type IV) hypersensitivity but initiated by UV-induced modification of the chemical into a complete antigen or hapten-protein complex. The photoactivated chemical binds to carrier proteins in the stratum corneum, forming haptens that are processed by Langerhans cells and presented to T-lymphocytes, eliciting a sensitized immune response upon re-exposure. Common triggers include topical agents like fragrances, sunscreens (e.g., benzophenones), or halogenated salicylanilides, which absorb primarily UVA to form allergenic photoproducts. Unlike phototoxicity, photoallergy typically requires prior sensitization and manifests eccentrically beyond the application site due to circulating immune mediators. Wavelength specificity is critical, as the absorption spectrum of the chromophore determines the effective UV range; for instance, porphyrins may respond to visible light, but most photocontact cases involve UVA or UVB due to their prevalence in solar radiation. Systemic absorption broadens the risk, as oral medications like tetracyclines generate phototoxic metabolites that distribute to photoexposed areas, potentially causing widespread eruptions. Overall, these mechanisms highlight the role of photochemical activation in amplifying cutaneous toxicity or immunity, distinct from light-independent pathways in conventional contact dermatitis.

Clinical Presentation

Signs

Contact dermatitis manifests with distinct visible skin changes that vary by acuity and type. In acute cases, the primary signs include , presenting as localized redness at the site of contact, and , which causes swelling due to fluid accumulation in the . These may progress to vesicles—small, fluid-filled blisters—or bullae, larger blisters filled with clear fluid, particularly in allergic or severe irritant reactions. In chronic or subacute presentations, the skin develops scaling, characterized by dry, flaky , and fissuring, where cracks form in the thickened . Lichenification often emerges, resulting in leathery, hyperkeratotic plaques from repeated or . These changes reflect ongoing exposure and can lead to secondary , especially in individuals with darker skin tones, where post-inflammatory darkening appears as brown or gray patches rather than typical redness. The distribution of signs typically follows the pattern of exposure, often presenting in linear or geometric configurations that match the shape of the offending agent, such as a necklace outline from . In severe irritant cases, pustules—small, pus-filled elevations—may appear alongside and , indicating intense inflammatory response. These visible manifestations are frequently accompanied by intense itching, though the focus remains on observable alterations.

Symptoms

Patients with contact dermatitis commonly experience pruritus, an intense sensation of itching that serves as the hallmark symptom, especially in (ACD). This itching typically arises 24 to 72 hours after exposure to an and can persist until the irritant or is removed. Common presentations include itching on both cheeks due to contact with cosmetics, skincare products, facial cleansers, masks, dust, or pollen, often accompanied by redness and papules, with potential scarring resulting from scratching. In ACD, pruritus is often more prominent than in (ICD), where it may be accompanied by other sensations, and it frequently worsens at night due to circadian variations in sensitivity and reduced distractions, contributing to significant disruption in chronic cases. Burning and stinging sensations are also frequent subjective experiences, particularly in ICD and during acute exposures to irritants. These symptoms tend to predominate early in course and may occur even before visible changes appear, reflecting direct damage to the skin barrier. While less dominant in ACD, burning can still emerge alongside pruritus in response to inflammatory mediators. Pain and tenderness may develop in more severe presentations, such as during the vesicular or ulcerative stages of the condition. These sensations arise from blister formation, erosion, or secondary , making the affected area sensitive to touch and movement. In ICD, pain is often more acute due to caustic exposures, whereas in ACD, it may accompany widespread reactions. Systemic symptoms are rare but can occur in widespread or systemic contact dermatitis, manifesting as , , or general discomfort, particularly when allergens are ingested or absorbed internally. Chronic pruritus can further exacerbate disturbances, leading to in affected individuals.

Diagnosis

History and Physical Examination

The diagnosis of contact dermatitis begins with a thorough taking to identify potential triggers and contextualize the presentation. Clinicians should inquire about occupational exposures, such as chemicals, metals, or solvents in industries like healthcare, , or ; hobby-related contacts, including , , or jewelry handling; and everyday products like , soaps, detergents, or fragrances that may come into direct skin contact. The timeline of onset is critical, with acute cases often developing within hours to days after exposure (e.g., irritant reactions) or 24 to 72 hours for allergic responses, while chronic forms may show gradual progression over weeks with repeated low-level exposures leading to persistent symptoms. A personal or family of atopy, including atopic dermatitis, asthma, or allergic rhinitis, is also elicited, as it increases susceptibility to irritant contact dermatitis and may influence the severity of reactions. Physical examination focuses on inspecting the skin for characteristic patterns that guide suspicion toward contact dermatitis. The distribution of lesions often corresponds to exposure sites, such as hands and wrists in occupational cases, periorbital areas from , or linear streaks from plant contact like ; diffuse involvement may suggest airborne or widespread product use. Morphology varies by acuity: acute presentations feature well-demarcated , , vesicles, or bullae indicating intense , whereas chronic cases exhibit scaling, fissuring, , or lichenification from repeated . , a common sign, is typically sharply bordered and localized, helping differentiate from more generalized rashes. Differential diagnosis considerations during the examination include distinguishing contact dermatitis from mimics such as tinea infections (which may show annular scaling and require to rule out), (often flexural and pruritic with a history of but lacking sharp borders), and seborrheic dermatitis (greasy scales on the , face, or chest without clear exposure links). Severity is graded based on extent and intensity: mild involves limited or slight scaling without interference in daily activities; moderate includes induration, moderate , or involvement of larger areas causing discomfort; severe features extensive vesicles, bullae, oozing, or significant functional impairment. Patient education plays an integral role during the and examination, empowering individuals to recognize potential triggers through discussion of exposure patterns and distribution, which facilitates early avoidance and prevents recurrence.

Diagnostic Tests

Patch testing serves as the gold standard for diagnosing (ACD), involving the application of standardized allergens to the skin under occlusion to detect delayed-type reactions. The procedure typically applies patches containing potential allergens, such as metals, fragrances, or preservatives, to the patient's back for 48 hours, followed by initial readings at 48 hours and final readings at 96 hours to assess for , , or vesicles indicative of positive reactions. Standardized systems like the TRUE Test, which includes 35 common allergens in pre-loaded chambers, offer convenience and reproducibility, while custom trays allow for tailored testing based on patient and exposure risks. Positive reactions are graded from +1 (mild ) to +3 (vesicles and bullae), with relevance determined by correlation to clinical presentation. Skin prick testing has limited utility in contact dermatitis evaluation, as it primarily detects immediate IgE-mediated rather than the delayed T-cell response characteristic of ACD, and is occasionally used only to rule out mimics like urticaria or protein contact dermatitis. is rarely required for contact dermatitis but may be performed when the clinical picture is or to differentiate from other spongiotic dermatoses, revealing histologic features such as epidermal , acanthosis, and a superficial perivascular lymphocytic infiltrate without significant epidermal . Photopatch testing is specifically employed to identify photocontact , where allergens are applied in duplicate patches: one set occluded without light exposure and the other irradiated with UVA (typically 5 J/cm²) after 24-48 hours of occlusion, with readings at 48 and 96 hours post-irradiation to distinguish photoallergic from non-photoallergic reactions. A positive photopatch reaction, defined as confined to the irradiated site, confirms photoallergy, commonly to photoactive substances like sunscreens or fragrances. Recent advances include molecular techniques to detect hapten-specific T-cells in skin biopsies from patch test sites, enhancing clinical relevance assessment by identifying allergen-specific immune responses through or , as explored in 2024 studies on . These methods build on history-guided selection of test allergens to improve diagnostic precision in complex cases.

Prevention

Exposure Avoidance

Avoiding exposure to triggers is the cornerstone of managing contact dermatitis, requiring systematic identification and elimination of causative agents. Patients can begin by scrutinizing ingredient labels on , household items, and to detect common allergens such as , fragrances, or preservatives, which are frequently implicated in reactions. Mobile applications like the Contact Allergen Management Program (CAMP) from the American Contact Dermatitis Society and SkinSAFE facilitate this process by allowing users to scan barcodes or search product databases for allergen-free alternatives based on results. For cases of systemic contact dermatitis, where ingested substances exacerbate symptoms, elimination diets targeting specific allergens—such as low-nickel diets for metal-sensitive individuals or avoidance of in foods—have shown efficacy in reducing flares, though these should be supervised by a healthcare provider to prevent nutritional deficiencies. Lifestyle modifications further support exposure avoidance by substituting irritants with safer options. To minimize reactions from laundry detergents, clothing residues, and fabric treatments, switch to fragrance-free, dye-free, hypoallergenic laundry detergents; use extra rinse cycles and rewash clothes to remove residues; avoid fragranced fabric softeners and dryer sheets; and wash new and second-hand clothing thoroughly before wearing to remove potential chemical residues such as detergents, excess dyes, or other textile finishes. Transition to fragrance-free soaps and lotions to minimize reactions from volatile compounds. These measures reduce the risk of irritant or allergic contact dermatitis. In occupational settings, where irritants like solvents or metals are prevalent, employers may implement accommodations under (OSHA) guidelines, including job task reassignments or substitution of hazardous materials to eliminate contact risks, as well as limiting wet work exposure to less than 20% of the workday (e.g., under 2 hours per day) and using like ventilation or . These measures align with broader efforts to create allergen-reduced environments, particularly for common triggers identified through diagnostic patch testing, such as rubber accelerators or topical antibiotics. Patient education plays a vital role in sustaining avoidance, with resources like the CAMP program providing personalized lists of safe products and guidance on reading labels effectively. This tool, accessible via web and app, empowers individuals to proactively manage their condition by cross-referencing exposures against known allergens. Additionally, maintaining a symptom to log potential contacts, reactions, and timelines helps track recurrences and refine avoidance strategies over time.

Protective Strategies

When complete avoidance of potential irritants or allergens is not feasible, protective strategies play a crucial role in minimizing exposure and maintaining the integrity of the barrier in individuals prone to contact dermatitis. These methods emphasize barrier protection, maintenance, and environmental modifications to reduce the risk of both irritant and allergic reactions. Personal protective equipment (PPE) is essential for shielding the skin from direct contact with hazardous substances. Gloves made from are preferred over due to the lower risk of , though accelerator-free variants are recommended to avoid sensitization to rubber accelerators that can cause . Cotton-lined gloves provide additional comfort and absorb moisture to prevent occlusion, which can exacerbate ; users should avoid prolonged continuous wear, change gloves frequently, and allow skin to breathe between uses. Protective clothing, such as long-sleeved shirts, pants, and aprons made from impermeable materials like vinyl or , helps block exposure in high-risk settings, but should be loose-fitting to avoid friction-induced dermatitis. Skin care routines support the skin's natural barrier function and are particularly important after potential exposure. For showering and bathing, use mild, fragrance-free, non-soap cleansers (e.g., Cetaphil or CeraVe); limit showers to short durations (approximately 5-10 minutes) with lukewarm water; pat the skin dry gently rather than rubbing; and moisturize immediately after to lock in hydration and maintain the barrier. Frequent application of fragrance-free, hypoallergenic moisturizers—such as those containing ceramides or petrolatum—helps restore lipid layers and prevent transepidermal water loss, with evidence showing reduced dermatitis incidence when applied multiple times daily, especially post-washing. pH-balanced cleansers (ideally with a pH of 5.5 to match skin's natural acidity) or syndet (synthetic detergent) bars are advised over alkaline soaps, as they minimize disruption to the stratum corneum and reduce irritation risk. Hands should be patted dry gently rather than rubbed, followed immediately by moisturizer to lock in hydration. In occupational settings, where exposure to chemicals or wet work is common, guidelines focus on engineering and to complement PPE. Adequate ventilation systems, such as local exhaust hoods, reduce airborne irritants that may settle on , while chemical substitution—replacing high-risk agents like chromates with safer alternatives—lowers overall exposure potential. Comprehensive programs educate workers on recognizing hazards, proper PPE donning/doffing, and protection techniques, with studies demonstrating significant reductions in cases through such interventions. For special populations, tailored strategies address unique exposure risks. In children, selecting toys made from materials—avoiding nickel-plated metals, rubber, or formaldehyde-releasing resins in items like jewelry, electronics, or adhesives—prevents ; parental supervision and barrier creams during play can further mitigate contact. Elderly individuals, often handling multiple topical medications, benefit from using gloves during application to avoid direct exposure to potential allergens like preservatives or antibiotics in creams, with added emphasis on moisturizing to counteract age-related barrier thinning.

Treatment

Treatment of contact dermatitis primarily involves avoidance of the irritant or , which is the cornerstone of , with pharmacological interventions used as adjuncts to control symptoms and .

Topical Therapies

Topical corticosteroids are the first-line therapy for managing in contact dermatitis, with potency selected based on the affected body area and severity to minimize side effects such as atrophy. Low-potency options, like 1%, are preferred for sensitive areas such as the face to reduce risks of adverse effects, while mid- to high-potency corticosteroids, such as triamcinolone 0.1%, 0.05%, fluticasone 0.05%, methylprednisolone aceponate 0.1%, or mometasone 0.1%, are suitable for thicker regions like the hands in moderate to severe cases. Treatment duration is typically limited to 10 to 21 days for moderate to severe presentations to prevent complications like dermal thinning, with tapering recommended upon improvement. Calcineurin inhibitors, including ointment and cream, serve as effective steroid-sparing alternatives, particularly for sensitive areas like the face, eyelids, or regions where long-term use is contraindicated due to higher risk, or if corticosteroids are ineffective. These agents inhibit T-cell activation and reduce inflammation without the atrophogenic effects of steroids, making them suitable for maintenance therapy in recurrent or chronic contact dermatitis, though they may cause transient burning upon application. Emollients and barrier creams play a crucial supportive role in restoring barrier function and preventing exacerbation in contact dermatitis. Petrolatum-based emollients, such as white petrolatum, provide occlusion to enhance hydration and repair the , applied liberally after bathing to maintain skin integrity. For , barrier creams containing dimethicone form a protective against external irritants like or chemicals, particularly beneficial in occupational settings involving wet work. Topical antihistamines may offer limited relief for pruritus in contact dermatitis, primarily through effects rather than histamine blockade, but their efficacy is modest in allergic cases where is non-histaminergic. Agents like diphenhydramine cream are occasionally used adjunctively, though systemic antihistamines are more commonly recommended, and topical formulations should be avoided in extensive areas to prevent . The 2024 Russian clinical guidelines for contact dermatitis emphasize elimination of contact with the irritant or allergen as the cornerstone of treatment, particularly for hand involvement, with topical corticosteroids (e.g., fluticasone 0.05%, methylprednisolone aceponate 0.1%, mometasone 0.1%) as first-line, calcineurin inhibitors (tacrolimus or pimecrolimus) if corticosteroids are ineffective, systemic antihistamines for itching, and short-term systemic corticosteroids (e.g., prednisolone) for severe or widespread cases. Moisturizers and avoidance of triggers are essential. No specific national guidelines exist for Tajikistan, but treatments are likely similar to Russian or international standards due to regional medical practices. Supportive topical measures include regular moisturization to maintain and repair the skin barrier, application of cool wet compresses to provide relief from itching and inflammation, and use of over-the-counter 1% hydrocortisone cream for mild to moderate pruritus. Patients should avoid scratching affected areas and minimize exposure to known irritants or allergens. For severe or persistent cases, consultation with a healthcare provider is recommended, as avoidance of triggers remains key to effective management.

Systemic Therapies

Systemic therapies are indicated for moderate-to-severe or widespread contact dermatitis, particularly when topical treatments alone are insufficient to control , swelling, or extensive involvement. These approaches target the underlying systemically and are typically reserved for acute flares or refractory cases, with careful consideration of risks versus benefits due to potential adverse effects. Oral corticosteroids, such as , are a cornerstone for managing acute severe affecting more than 20% of the . A typical regimen involves an initial dose of 0.5-1 mg/kg per day for adults, administered as a short burst over 7-14 days, followed by a gradual taper to prevent rebound flares. Shorter courses without tapering increase the risk of relapse, as seen in cases like dermatitis. These agents rapidly reduce and pruritus but are not recommended for long-term use due to side effects including , , and . For chronic or refractory allergic contact dermatitis unresponsive to corticosteroids and allergen avoidance, immunosuppressants like cyclosporine or may be employed. Cyclosporine, dosed at 3-5 mg/kg/day, has demonstrated efficacy in severe recalcitrant cases by inhibiting T-cell activation, though challenges arise upon withdrawal due to potential disease rebound. , typically administered at low weekly doses (e.g., 15-25 mg), offers comparable effectiveness to other immunomodulators, with retrospective studies showing significant improvement in symptoms and tolerability in patients with persistent disease. Both require regular monitoring for side effects, including renal function, liver enzymes, and for cyclosporine, as well as for . Oral antihistamines, particularly H1-blockers like or diphenhydramine, provide symptomatic relief for pruritus in contact dermatitis, especially when combined with topical therapies as an adjunct. Sedating formulations aid sleep disruption from itching, while non-sedating options like loratadine support daytime control, though their anti-inflammatory effects are limited compared to steroids. Treatment decisions align with expert guidelines from organizations like the and standard dermatologic practice, emphasizing short-term use of systemic agents with ongoing patch testing to identify triggers and prevent recurrence. Patients on these therapies should undergo baseline and periodic assessments for adverse effects, such as monitoring for risk with corticosteroids or immunosuppressants.

Advanced and Emerging Treatments

Advanced and emerging treatments for contact dermatitis focus on targeted and preventive strategies, particularly for or widespread cases where standard therapies prove insufficient. Biologic agents, such as , an interleukin-4 and interleukin-13 inhibitor, have shown promise in managing (ACD) that overlaps with atopic features, by reducing Th2-mediated and improving clinical symptoms in patients unresponsive to avoidance. of has demonstrated variable efficacy, with some patients experiencing significant eczema resolution, though patch test reactivity may persist inconsistently. Ongoing clinical investigations, including a 2025 trial evaluating its effects on ACD, aim to clarify its role in non-atopic predominant cases. Anti-tumor necrosis factor (TNF) agents, including infliximab, adalimumab, etanercept, and certolizumab pegol, represent another biologic frontier for ACD, targeting TNF-α's role in hapten-induced inflammation and T-cell activation. Preliminary data suggest these agents may benefit severe, chronic ACD by dampening cytokine-driven responses. Janus kinase (JAK) inhibitors, particularly topical ruxolitinib, offer rapid anti-inflammatory effects for chronic hand eczema associated with ACD, inhibiting JAK1/JAK2 signaling to reduce cytokine production and skin barrier disruption. In phase 2 trials, ruxolitinib 1.5% cream achieved significant improvements in disease severity and quality of life by week 16, with over 50% of non-atopic patients reaching clear or almost clear status, and it was well-tolerated without new safety concerns. This topical approach minimizes systemic exposure, providing a targeted option for localized, refractory cases. Phototherapy with narrowband B (NB-UVB) serves as an emerging adjunct for widespread ACD, modulating immune responses in the skin while carefully avoiding wavelengths that could exacerbate photoallergic reactions. Administered at doses starting from 50-70% of the minimal dose and escalating gradually, NB-UVB has demonstrated efficacy in reducing inflammatory infiltrates in eczematous conditions akin to ACD, with sessions typically three times weekly to achieve symptom control without long-term risks. Hapten-specific vaccines, such as PDC-APB, function as immunotherapies to desensitize against common allergens like in /oak, preventing ACD onset by inducing tolerance via controlled exposure. Phase 1 trials completed in 2021 have confirmed its safety and dermal tolerability in ascending doses. modulation strategies, including dietary interventions and fecal microbiota transplantation, aim to alter gut-skin axis dynamics and reduce susceptibility to contact by promoting microbial profiles. Studies indicate that such approaches can attenuate Th2 responses and enhance barrier integrity, potentially averting ACD in at-risk populations.

Complications and Prognosis

Complications

Contact dermatitis, particularly when untreated or recurrent, can predispose individuals to secondary bacterial infections due to disruption of the skin barrier, allowing entry of pathogens such as and . These infections commonly manifest as , characterized by honey-crusted lesions, or more severe involving deeper tissue inflammation and potential systemic symptoms. The risk is heightened in cases with extensive scratching or excoriation, which further compromises the epidermal integrity. Chronic sequelae from prolonged or severe contact dermatitis include post-inflammatory hyperpigmentation, where affected areas develop darkened patches due to deposition following resolution. In more intense or repeated episodes, scarring may occur, often secondary to scratching or oozing, particularly in facial cases such as on the cheeks, and especially if secondary infections lead to deeper tissue damage, resulting in permanent textural changes. Severe, widespread cases can progress to erythroderma, an exfoliative inflammatory state covering much of the body surface, which arises infrequently from but carries significant morbidity. The persistent itch and visible lesions associated with chronic contact dermatitis contribute to substantial psychological distress, including elevated rates of anxiety and depression. Patients often report emotional burdens such as embarrassment and social withdrawal, exacerbated by the relapsing nature of the condition, leading to reduced quality of life. Occupationally, contact dermatitis accounts for a notable proportion of work-related disabilities, with prevalence estimates of 6.7% to 10.6% among exposed workers and responsibility for up to 25% of lost workdays in affected professions. High-risk occupations like healthcare, construction, and manufacturing see higher incidences, potentially resulting in job changes or early retirement due to persistent symptoms.

Prognosis

The prognosis for acute contact dermatitis is generally excellent when the triggering agent is and avoided, with most cases resolving within 2 to 4 weeks. Isolated episodes, particularly those due to irritants, often heal completely without long-term sequelae if exposure ceases promptly. In chronic or recurrent cases, outcomes are more variable and depend heavily on addressing underlying triggers. If causative agents remain unaddressed, persistence or recurrence occurs in 50-70% of patients with (ACD), as leads to lifelong reactivity upon re-exposure. In contrast, (ICD) tends to have a better than ACD, as it does not involve immune and resolves more reliably with irritant avoidance, though repeated exposure can lead to cumulative skin barrier damage. Key prognostic factors include early and patient compliance with avoidance measures, which significantly improve recovery rates. Conversely, a history of or advanced age worsens outcomes, as atopic individuals have impaired skin barriers predisposing to prolonged , while elderly patients face challenges with compliance and thinner skin increasing vulnerability. Secondary complications, such as infections, can further deteriorate the outlook by prolonging healing. Recent studies emphasize the efficacy of structured avoidance programs, with approximately 80% of patients reporting improvement in symptoms following patch testing and targeted avoidance guidance. These programs, incorporating on safe alternatives, enhance long-term management and reduce recurrence.

References

  1. https://www.mayoclinic.org/diseases-conditions/contact-dermatitis/symptoms-causes/syc-20352742
  2. https://my.clevelandclinic.org/health/diseases/6173-contact-dermatitis
  3. https://www.ncbi.nlm.nih.gov/books/NBK459230/
  4. https://pmc.ncbi.nlm.nih.gov/articles/PMC10239928/
  5. https://pubmed.ncbi.nlm.nih.gov/30370565/
  6. https://pmc.ncbi.nlm.nih.gov/articles/PMC3276771/
  7. https://dermnetnz.org/topics/textile-contact-dermatitis
  8. https://dermnetnz.org/topics/textile-dye-allergy
  9. https://pubmed.ncbi.nlm.nih.gov/10592001/
  10. https://pmc.ncbi.nlm.nih.gov/articles/PMC3391944/
  11. https://www.mayoclinic.org/diseases-conditions/contact-dermatitis/diagnosis-treatment/drc-20352748
  12. https://www.aafp.org/pubs/afp/issues/2010/0801/p249.html
  13. https://pubmed.ncbi.nlm.nih.gov/28357521/
  14. https://pubmed.ncbi.nlm.nih.gov/23806165/
  15. https://www.uptodate.com/contents/contact-dermatitis-including-latex-dermatitis-beyond-the-basics/print
  16. https://www.merckmanuals.com/professional/dermatologic-disorders/dermatitis/contact-dermatitis
  17. https://dermnetnz.org/topics/photocontact-dermatitis
  18. https://dermnetnz.org/topics/occupational-skin-disease
  19. https://dermnetnz.org/topics/systemic-contact-dermatitis
  20. https://pubmed.ncbi.nlm.nih.gov/29766368/
  21. https://pubmed.ncbi.nlm.nih.gov/39403761/
  22. https://link.springer.com/article/10.1007/s40629-023-00246-9
  23. https://www.dermatologytimes.com/view/allergic-contact-dermatitis-remains-prevalent-negatively-impacts-quality-of-life
  24. https://journals.lww.com/jdds/fulltext/2024/07000/self_reported_occupational_related_contact.2.aspx
  25. https://pmc.ncbi.nlm.nih.gov/articles/PMC8248138/
  26. https://journals.sagepub.com/doi/10.1177/17103568251392229
  27. https://aoemj.org/journal/view.php?number=1517
  28. https://onlinelibrary.wiley.com/doi/10.1111/cod.14818
  29. https://www.hmpgloballearningnetwork.com/site/thederm/feature-story/whats-new-allergic-contact-dermatitis-2025s-allergens-rise
  30. https://onlinelibrary.wiley.com/doi/abs/10.1111/cod.13119
  31. https://pmc.ncbi.nlm.nih.gov/articles/PMC9324524/
  32. https://bmcpublichealth.biomedcentral.com/articles/10.1186/s12889-024-17836-z
  33. https://pmc.ncbi.nlm.nih.gov/articles/PMC9903276/
  34. https://www.occupationalcancer.ca/contact-dermatitis/
  35. https://dermnetnz.org/topics/irritant-contact-dermatitis
  36. https://www.actasdermo.org/en-allergic-contact-dermatitis-plants-understanding-articulo-S1578219012001989
  37. https://pmc.ncbi.nlm.nih.gov/articles/PMC8953884/
  38. https://pubmed.ncbi.nlm.nih.gov/31782153/
  39. https://www.frontiersin.org/journals/public-health/articles/10.3389/fpubh.2023.1189190/epub
  40. https://www.nature.com/articles/s41572-021-00271-4
  41. https://pmc.ncbi.nlm.nih.gov/articles/PMC8989112/
  42. https://www.longdom.org/open-access/irritant-contact-dermatitis-mechanisms-to-repair-10724.html
  43. https://pmc.ncbi.nlm.nih.gov/articles/PMC3858878/
  44. https://pubmed.ncbi.nlm.nih.gov/10022266/
  45. https://plasticsurgerykey.com/irritant-contact-dermatitis-5/
  46. https://emedicine.medscape.com/article/1049353-overview
  47. https://www.uptodate.com/contents/basic-mechanisms-and-pathophysiology-of-allergic-contact-dermatitis
  48. https://www.ncbi.nlm.nih.gov/books/NBK532866/
  49. https://link.springer.com/article/10.1007/s40521-022-00299-1
  50. https://pmc.ncbi.nlm.nih.gov/articles/PMC3578582/
  51. https://www.jacionline.org/article/S0091-6749%2805%2980238-6/pdf
  52. https://onlinelibrary.wiley.com/doi/full/10.1038/icb.2010.114
  53. https://pubmed.ncbi.nlm.nih.gov/16296151/
  54. https://www.jidonline.org/article/S0022-202X%2819%2931344-2/fulltext
  55. https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2020.00874/full
  56. https://pubmed.ncbi.nlm.nih.gov/14657881/
  57. https://pubmed.ncbi.nlm.nih.gov/29951786/
  58. https://pmc.ncbi.nlm.nih.gov/articles/PMC9552952/
  59. https://pmc.ncbi.nlm.nih.gov/articles/PMC8401619/
  60. https://pmc.ncbi.nlm.nih.gov/articles/PMC11355232/
  61. https://pmc.ncbi.nlm.nih.gov/articles/PMC7698592/
  62. https://pmc.ncbi.nlm.nih.gov/articles/PMC8459281/
  63. https://dermnetnz.org/topics/contact-dermatitis
  64. https://www.aad.org/public/diseases/eczema/types/contact-dermatitis/symptoms
  65. https://www.webmd.com/skin-problems-and-treatments/eczema/atopic-vs-contact-dermatitis
  66. https://mdedge.com/cutis/article/213768/contact-dermatitis/systemic-contact-dermatitis-sometimes-it-food
  67. https://www.epocrates.com/online/diseases/90/contact-dermatitis
  68. https://doi.org/10.1111/cod.12432
  69. https://my.clevelandclinic.org/health/diagnostics/patch-test
  70. https://dermnetnz.org/topics/patch-tests
  71. https://gwdocs.org/specialties/dermatology/patch-testing-and-photopatch-testing
  72. https://pmc.ncbi.nlm.nih.gov/articles/PMC4763571/
  73. https://onlinelibrary.wiley.com/doi/10.1111/cod.14657
  74. https://www.jaadreviews.org/article/S2950-1989%2825%2900038-8/fulltext
  75. https://www.contactderm.org/resources/acds-camp/camp-for-patients/basics
  76. https://www.skinsafeproducts.com/apps
  77. https://pubmed.ncbi.nlm.nih.gov/23169206/
  78. https://www.aad.org/public/everyday-care/itchy-skin/rash/itchy-rash-contact-dermatitis
  79. https://www.osha.gov/dermal-exposure
  80. https://www.theminorsurgerycenter.com/blog/contact-dermatitis-explained
  81. https://dermnetnz.org/topics/contact-dermatitis-to-nitrile
  82. https://pmc.ncbi.nlm.nih.gov/articles/PMC2868883/
  83. https://www.jacionline.org/article/S0091-6749%2823%2901724-4/fulltext
  84. https://www.aaaai.org/tools-for-the-public/conditions-library/allergies/skin-care-tips-atopic-dermatits
  85. https://www.sciencedirect.com/science/article/abs/pii/019096229070284O
  86. https://www.publichealthontario.ca/-/media/documents/g/2019/guide-occupational-dermatitis.pdf
  87. https://dermnetnz.org/topics/allergic-contact-dermatitis-in-children
  88. https://onlinelibrary.wiley.com/doi/10.1111/cod.13500
  89. https://www.aafp.org/pubs/afp/issues/2009/0115/p135.html
  90. https://pubmed.ncbi.nlm.nih.gov/16451787/
  91. https://pmc.ncbi.nlm.nih.gov/articles/PMC4484750/
  92. https://www.ncbi.nlm.nih.gov/books/NBK558995/
  93. https://emedicine.medscape.com/article/1049353-treatment
  94. https://pmc.ncbi.nlm.nih.gov/articles/PMC8974693/
  95. https://diseases.medelement.com/disease/%D0%B4%D0%B5%D1%80%D0%BC%D0%B0%D1%82%D0%B8%D1%82-%D0%BA%D0%BE%D0%BD%D1%82%D0%B0%D0%BA%D1%82%D0%BD%D1%8B%D0%B9-%D0%BA%D1%80-%D1%80%D1%84-2024/18204
  96. https://www.aad.org/public/diseases/eczema/types/contact-dermatitis/treatment
  97. https://emedicine.medscape.com/article/1049216-treatment
  98. https://publications.aap.org/pediatriccare/article/doi/10.1542/aap.ppcqr.396149/1582/Contact-Dermatitis
  99. https://pubmed.ncbi.nlm.nih.gov/30570582/
  100. https://pubmed.ncbi.nlm.nih.gov/29210087/
  101. https://www.aaaai.org/tools-for-the-public/conditions-library/allergies/contact-dermatitis-overview
  102. https://emedicine.medscape.com/article/1049216-medication
  103. https://pubmed.ncbi.nlm.nih.gov/35856769/
  104. https://academic.oup.com/bjd/article/193/Supplement_1/ljaf085.292/8162117
  105. https://clinicaltrials.gov/study/NCT03935971
  106. https://www.sciencedirect.com/science/article/pii/S000173102500376X
  107. https://pubmed.ncbi.nlm.nih.gov/40889714/
  108. https://www.sciencedirect.com/science/article/abs/pii/S0190962225027173
  109. https://clinicaltrials.gov/study/NCT05293717
  110. https://pmc.ncbi.nlm.nih.gov/articles/PMC8634827/
  111. https://www.aetna.com/cpb/medical/data/200_299/0205.html
  112. https://www.haptensciences.com/products/
  113. https://clinicaltrials.gov/study/NCT04853823
  114. https://pmc.ncbi.nlm.nih.gov/articles/PMC10060339/
  115. https://pmc.ncbi.nlm.nih.gov/articles/PMC12545045/
  116. https://patient.info/doctor/dermatology/contact-and-occupational-dermatitis
  117. https://www.aafp.org/pubs/afp/issues/2002/0701/p119.html
  118. https://www.sciencedirect.com/science/article/pii/S235251262200515X
  119. https://www.ncbi.nlm.nih.gov/books/NBK559150/
  120. https://journals.sagepub.com/doi/10.1177/2165079914565351
  121. https://my.clevelandclinic.org/health/diseases/4089-dermatitis
  122. https://dermnetnz.org/topics/erythroderma
  123. https://pubmed.ncbi.nlm.nih.gov/18318886/
  124. https://pubmed.ncbi.nlm.nih.gov/2144814/
  125. https://www.researchgate.net/publication/341139820_Occupational_Contact_Dermatitis
  126. https://www.liebertpub.com/doi/10.1089/derm.2023.0269
  127. https://onlinelibrary.wiley.com/doi/abs/10.1111/cod.12912
  128. https://pmc.ncbi.nlm.nih.gov/articles/PMC10558003/
  129. https://pmc.ncbi.nlm.nih.gov/articles/PMC6109020/
Add your contribution
Related Hubs
User Avatar
No comments yet.